Helix BioPharma Corp.
TSX : HBP
FRANKFURT : HBP

Helix BioPharma Corp.

July 31, 2017 16:33 ET

Helix Biopharma Corp. to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Immune checkpoint modulation by urease-mediated alkalization

TORONTO, ONTARIO--(Marketwired - July 31, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that the Company's poster entitled: "Immune checkpoint modulation by urease-mediated alkalization", has been accepted for presentation in the "Checkpoint Blockade Therapy" session at the Third International Cancer lmmunotherapy Conference. The conference is being held in Mainz Germany on September 6th through to the 9th, 2017 at the Rheingoldhalle Congress Center Mainz. Dr. Heman Chao, Helix's Chief Executive Officer, will be presenting on September 6th, 2017 at 6:00 pm. A copy of the presentation will be available on the Company's website on the same day.

"We are very excited to share our latest L-DOS47 immune-oncology research results with the scientific community," said Dr. Heman Chao. "This body of work, including the recently announced collaboration with Dr. Robert Gillies of the Moffitt Cancer Center, is part of Helix's ongoing efforts to showcase the novel characteristics of L-DOS47 and its potential in complementing checkpoint inhibitors and other immunotherapies."

About L-DOS47

L-DOS47 is an immunoconjugate based drug candidate in development based on the Company's novel DOS47 platform technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction.

About Helix BioPharma Corp.

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Cautionary Statements

This news release may contain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws including, without limitation, those relating to Helix's operations and strategy and its research and development activities. These statements generally can be identified by forward looking words such as "ongoing", "excited", "efforts", "will" or "modify", and other similar expressions, are intended to provide information about management's current plans and expectations.

Forward-looking statements include, without limitation, statements concerning (i) the Company's ability to operate on a going concern being dependent mainly on obtaining additional financing; (ii) the Company's priority continuing to be L-DOS47; (iii) the Company's development programs for DOS47 and L-DOS47; (iv) future expenditures, the insufficiency of the Company's current cash resources and the need for financing; and (v) future financing requirements and the seeking of additional funding. Forward-looking statements can further be identified by the use of forward-looking terminology such as "ongoing", "estimates", "expects", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", or "should" occur or be achieved, or comparable terminology referring to future events or results.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, risks inherent in Helix's research and development activities and those risks and uncertainties affecting the Company, as more fully described in Helix's most recent Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors, estimates or assumptions have been applied in making forward-looking statements including, without limitation, the safety and efficacy of the Company's drug product candidates; that sufficient financing will be obtained in a timely manner to allow the Company to continue operations and implement its clinical trials in the manner and on the timelines anticipated; the timely provision of services and supplies or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; the timely receipt of required regulatory approvals and strategic partner support and that the factors described in the Helix Risk Factors will not cause the Company's actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions, opinions, plans and expectations of Helix's management on the date of this news release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions, plans or expectations, or other circumstances change, except as required by law.

Contact Information